Idorsia and Viatris successfully close the transaction for the global research and development collaboration
18 Marzo 2024 - 7:00AM
UK Regulatory
Idorsia and Viatris successfully close the transaction for the
global research and development collaboration
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – March 18, 2024
Idorsia Ltd (SIX: IDIA) today announced that it has successfully
closed the transaction with Viatris Inc. (NASDAQ: VTRS), a global
healthcare company, for the global research and development
collaboration, focused on the development and commercialization of
two innovative compounds, selatogrel and cenerimod, discovered by
Idorsia.
The upfront consideration of USD 350 million has now been fully
paid by Viatris to Idorsia.
Further details will be provided with the combined Full Year
2023 and First Quarter 2024 financial reporting on April
25th.
The selatogrel and cenerimod programs will be discussed at an
upcoming R&D day of our partner Viatris.
Notes to the editor
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely
positioned to bridge the traditional divide between generics and
brands, combining the best of both to more holistically address
healthcare needs globally. With a mission to empower people
worldwide to live healthier at every stage of life, we provide
access at scale, currently supplying high-quality medicines to
approximately 1 billion patients around the world annually and
touching all of life’s moments, from birth to the end of life,
acute conditions to chronic diseases. With our exceptionally
extensive and diverse portfolio of medicines, a one-of-a-kind
global supply chain designed to reach more people when and where
they need them, and the scientific expertise to address some of the
world’s most enduring health challenges, access takes on deep
meaning at Viatris. We are headquartered in the U.S., with global
centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at
viatris.com and investor.viatris.com, and connect with us on
LinkedIn, Instagram, YouTube and X (formerly Twitter).
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see
more opportunities and we want to help more patients. In order to
achieve this, we will develop Idorsia into a leading
biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub –
Idorsia is specialized in the discovery, development and
commercialization of small molecules to transform the horizon of
therapeutic options. Idorsia has a 20-year heritage of drug
discovery, a broad portfolio of innovative drugs in the pipeline,
an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe and North
America – the ideal constellation for bringing innovative medicines
to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol:
IDIA) in June 2017 and has over 800 highly qualified specialists
dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate
Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123
Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking
statements", relating to the company's business, which can be
identified by the use of forward-looking terminology such as
"estimates", "believes", "expects", "may", "are expected to",
"will", "will continue", "should", "would be", "seeks", "pending"
or "anticipates" or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions
of the company's investment and research and development programs
and anticipated expenditures in connection therewith, descriptions
of new products expected to be introduced by the company and
anticipated customer demand for such products and products in the
company's existing portfolio. Such statements reflect the current
views of the company with respect to future events and are subject
to certain risks, uncertainties and assumptions. Many factors could
cause the actual results, performance or achievements of the
company to be materially different from any future results,
performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or
expected.
Grafico Azioni Idorsia (LSE:0RQE)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Idorsia (LSE:0RQE)
Storico
Da Mag 2023 a Mag 2024